Recent developments include the separation of the CAH program into a new company, planned regulatory submission for TA-ERT, management appointments, and financing activities.

• Spruce Biosciences separated its Congenital Adrenal Hyperplasia (CAH) program into a new company named Adrenyx Biosciences in November 2026 [N1].
• The company confirmed a planned Biologics License Application (BLA) submission for its TA-ERT therapy in Q4 2026 following positive FDA meetings [N4].
• Spruce launched an MPS IIIB resource website ahead of a planned TA-ERT study in Q4 2026 [N3].
• Spruce Biosciences reported a widened Q2 loss and named Adrian Quarterl as Chief Medical Officer and Jessica Cohen as Vice President - Clinical in August 2026 [N5].
• Craig-Hallum and Lake Street initiated coverage of Spruce Biosciences with buy recommendations in 2026 [N6][N2].
• The company priced a $60 million public offering of shares and pre-funded warrants in April 2026 to fund neuro therapies [N7][N8].

Spruce Biosciences has advanced its TA-ERT therapy to a late-stage clinical development milestone with planned BLA submission in Q4 2026 following positive FDA interactions and Breakthrough Therapy Designation. The company has secured financing to support its neuro therapies pipeline and has streamlined its focus by spinning off the CAH program. Positive analyst coverage and management appointments support ongoing execution. Successful regulatory approval and commercialization of TA-ERT could enhance the company's strategic position in rare neurological disorders.

Spruce Biosciences operates with significant losses and no current revenue, raising going concern considerations. The company depends on successful clinical development and regulatory approval of its therapies, which carry inherent risks and uncertainties. The spin-off of the CAH program may reduce pipeline diversification. Continued operating losses and cash burn require ongoing financing, which may dilute shareholders. Failure to achieve regulatory milestones or commercial success could materially impact the company's prospects.

Spruce Biosciences' moat is based on its focus on developing novel therapies for rare neurological disorders with significant unmet medical needs, leveraging regulatory designations such as FDA Breakthrough Therapy to potentially expedite development and approval. The company's specialized clinical programs and intellectual property around TA-ERT and other therapies contribute to its competitive positioning. However, as a clinical-stage biopharmaceutical company without commercial products or revenue, its moat is contingent on successful clinical development and regulatory approvals.

• Clinical and Regulatory Risk: The company’s therapies are in clinical development and subject to regulatory approval processes that involve uncertainty and potential delays or failures.
• Financial Risk: Spruce Biosciences has incurred significant losses and negative cash flows, with substantial doubt about its ability to continue as a going concern without additional financing.
• Operational Risk: The spin-off of the CAH program into a separate company may impact the company’s pipeline breadth and operational focus.
• Market and Competitive Risk: The company operates in a competitive biopharmaceutical environment targeting rare neurological disorders, with risks from competing therapies and market acceptance.

• Spruce Biosciences, Inc. operates as a single segment company focused on developing and commercializing novel therapies for serious neurological disorders with significant unmet medical need [S1].
• The company has incurred significant losses and negative cash flows from operations and does not expect positive cash flows from operations in the foreseeable future, raising substantial doubt about its ability to continue as a going concern [S1].
• As of September 30, 2026, Spruce Biosciences had cash and cash equivalents of $87.7 million, current assets of $90.3 million, and current liabilities of $18.7 million, resulting in a current ratio of 4.83 and a cash ratio of 4.69 [S2].
• The company reported a net loss of $24.0 million for the nine months ended September 30, 2026, with basic and diluted EPS of -$8.51 per share [S2].
• For the year ended December 31, 2025, the company had zero revenue, research and development expenses of $19.5 million, general and administrative expenses of $17.0 million, and a net loss of $39.0 million [S1].
• Spruce Biosciences issued pre-funded warrants in January 2025 representing 4.99% of outstanding common stock upon exercise; these are recorded as liabilities with changes in fair value impacting the statement of operations [S1].
• The company completed a $60 million public offering of shares and pre-funded warrants in April 2026 to fund neuro therapies [N7][N8].
• Spruce Biosciences confirmed a planned Biologics License Application (BLA) submission for its TA-ERT therapy in Q4 2026 following positive FDA meetings [N4].
• The TA-ERT therapy has received FDA Breakthrough Therapy Designation [N4][N10].
• Spruce launched an MPS IIIB resource website ahead of a planned TA-ERT study in Q4 2026 [N3].
• The company separated its Congenital Adrenal Hyperplasia (CAH) program into a new company named Adrenyx Biosciences in November 2026 [N1].
• Recent management appointments include Adrian Quarterl as Chief Medical Officer and Jessica Cohen as Vice President - Clinical [N5].
• Multiple investment firms initiated or maintained coverage with buy or outperform recommendations in 2026, including Lake Street and Craig-Hallum [N2][N6].